SciBX: Science-Business eXchange Contents: November 1 2012, Volume 5 / Issue 43

TABLE OF CONTENTS November 1 2012, Volume 5 / Issue 43 Analysis Cover Story Translational Notes Targets and Mechanisms The Distillery: Therapeutics Autoimmune disease Cancer Cardiovascular disease Endocrine/metabolic disease Infectious disease Neurology Pulmonary disease Renal disease Various The Distillery: Techniques Drug platforms Markers The publication of this issue was delayed due to Hurricane Sandy closing our New York offices temporarily. We apologize for any inconvenience caused. New Partnering Opportunities in Alzheimer's Disease! A comprehensive interactive dashboard from Relay Technology Management.  Click here for more information on Alzheimer's partnering opportunities.   SciBX: Science-Business eXchange Recommend SciBX to your library today SciBx is a weekly publication that identifies and analyzes the most important translational research articles from over 40 journals. Find out which papers have real scientific and commercial potential, and why. Subscribe to SciBX and you won't miss the next big thing. For more information visit: www.nature.com/scibx.   Trade Secrets A Nature Network blog by BIOENTREPRENEUR Brought to you by Nature Biotechnology Access the insights, advice and commentary from scientists and entrepreneurs building biotech sectors around the world. Join the global dialogue on life science entrepreneurship: http://blogs.nature.com/trade_secrets   Analysis Cover Story Top Revving up glycolysis Joanne Kotz doi:10.1038/scibx.2012.1127 A trio of papers has provided new hints on how best to use activators of PKM2, a target involved in cancer cell metabolism. Astex is using its findings to steer an early stage PKM2 program, whereas Agios is remaining mum on the direction of its PKM2 program. Full Text | PDF Translational Notes Top Mess with Texas Lev Osherovich doi:10.1038/scibx.2012.1128 The disintegration of the Cancer Prevention & Research Institute of Texas' scientific board is a lesson in how not to manage perceived conflict between commercial and scientific interests at philanthropic research foundations. Full Text | PDF From bedside to bench Kai-Jye Lou doi:10.1038/scibx.2012.1129 The recently announced oncology R&D collaboration between Sanofi and Massachusetts General Hospital takes a different tack than most translational research partnerships by starting with insights gleaned from the bedside setting and working their way back to the bench. Full Text | PDF Targets and Mechanisms Top Prime and pull against HSV-2 Michael J. Haas doi:10.1038/scibx.2012.1130 Yale researchers have mouse data showing that vaginal application of two chemokines recruits memory T cells into vaginal tissue and improves the protective effect of an HSV-2 vaccine. The team is now working to prolong the duration of the chemokines' effects and wants to extend the strategy to HIV prophylaxis. Full Text | PDF Distillery: Therapeutics Autoimmune disease Top IL-1 receptor-like 2 (IL1RL2; IL-36R) doi:10.1038/scibx.2012.1131 Mouse studies suggest antagonizing IL-36R could help treat psoriasis. Full Text | PDF Cancer Top FMS-like tyrosine kinase 3 (FLT3; CD135); aurora kinases doi:10.1038/scibx.2012.1132 In vitro and mouse studies identified inhibitors of aurora kinases and FLT3 that could help treat AML. Full Text | PDF Checkpoint kinase 1 (Chk1) doi:10.1038/scibx.2012.1133 Mouse studies identified a Chk1 inhibitor that could help treat cancer. Full Text | PDF Pyruvate kinase M2 isozyme (PKM2) doi:10.1038/scibx.2012.1134 In vitro and cell culture studies identified a serine-binding, allosteric activation site on PKM2 that could be targeted to help inhibit tumor growth. Full Text | PDF IL-9 doi:10.1038/scibx.2012.1135 Mouse studies suggest IL-9-producing T helper type 9 (Th9) cells could help treat melanoma. Full Text | PDF Unknown doi:10.1038/scibx.2012.1136 Mouse studies identified a water-soluble triptolide analog that could help treat pancreatic cancer. Full Text | PDF Aurora kinase B (AURKB; aurora-B); c-Myc (MYC) doi:10.1038/scibx.2012.1137 A cell screening study suggests aurora-B inhibitors could help treat SCLCs with MYC amplification. Full Text | PDF Cardiovascular disease Top MicroRNA-155 (miR-155) doi:10.1038/scibx.2012.1138 In vitro and mouse studies suggest inhibiting miR-155 could help treat atherosclerosis. Full Text | PDF Topoisomerase IIβ (TOP2B) doi:10.1038/scibx.2012.1139 Mouse studies suggest TOP2B expression could help predict the risk of doxorubicin-induced cardiomyopathy. Full Text | PDF Endocrine/metabolic disease Top Endoplasmic reticulum to nucleus signaling 1 (ERN1; IRE1) doi:10.1038/scibx.2012.1140 An SAR study identified small molecule modulators of IRE1 that could be useful for treating type 2 diabetes. Full Text | PDF Infectious disease Top B cell lymphoma 2 (BCL-2; BCL2); Bcl-xL doi:10.1038/scibx.2012.1141 Worm and cell culture studies suggest inhibiting BCL2-family proteins could help treat HBV infection. Full Text | PDF Neurology Top Nicotinic acetylcholine receptor α7 (CHRNA7) doi:10.1038/scibx.2012.1142 Rodent studies identified a CHRNA7 agonist that could help treat cognitive impairment associated with AD and schizophrenia. Full Text | PDF Potassium channel subfamily T member 1 (KCNT1) doi:10.1038/scibx.2012.1143 Genetic studies suggest activating mutations in KCNT1 could help diagnose malignant migrating partial seizures of infancy (MMPSI). Full Text | PDF Chemokine CX3C motif ligand 1 (CX3CL1; fractalkine) doi:10.1038/scibx.2012.1144 Mouse studies suggest the soluble isoform of CX3CL1 could help treat PD. Full Text | PDF Pulmonary disease Top Amphiregulin (AREG); epidermal growth factor receptor 1 (EGFR1; HER1; ErbB1); transforming growth factor-β1 (TGFB1) doi:10.1038/scibx.2012.1145 In vitro and mouse studies suggest inhibiting AREG-EGFR1 signaling could help treat idiopathic pulmonary fibrosis (IPF). Full Text | PDF Renal disease Top Adenosine A2 receptor (ADORA2) doi:10.1038/scibx.2012.1146 In vitro and mouse studies suggest ADORA2 agonist–treated dendritic cells (DCs) could help treat acute kidney injury. Full Text | PDF Various Top CC chemokine receptor 1 (CCR1; CD191) doi:10.1038/scibx.2012.1147 In vitro and mouse studies identified CCR1 antagonists that could help treat inflammation in RA and other diseases. Full Text | PDF Distillery: Techniques Drug platforms Top Cell-penetrating, DNA-targeting systemic lupus erythematosus (SLE) autoantibody 3E10 for sensitizing cancers to DNA-damaging agents doi:10.1038/scibx.2012.1148 In vitro and mouse studies suggest lupus autoantibodies targeting DNA could help sensitize tumors to DNA-damaging agents. Full Text | PDF Markers Top Mutations in fetal long noncoding RNA (lncRNA) as a diagnostic marker of hemolysis, liver enzymes and low platelets (HELLP) syndrome doi:10.1038/scibx.2012.1149 Human and in vitro studies suggest fetal lncRNA mutations could help diagnose HELLP syndrome in pregnant women. Full Text | PDF Plasma levels of the CDKN1A interacting zinc finger protein 1 (CIZ1) truncated variant to diagnose early stage lung cancer doi:10.1038/scibx.2012.1150 Patient sample and mouse studies suggest plasma levels of truncated CIZ1 could help diagnose early stage lung cancer. Full Text | PDF

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant) For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our customer feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2012 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.